EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Treating genetic blood disorders in the era of CRISPR-mediated genome editing

Alhomidi Almotiri, Ahmed Abogosh, Ali Abdelfattah, Dalya Alowaisy, Neil P Rodrigues

Molecular Therapy · 2025

DOI: 10.1016/j.ymthe.2025.01.031 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecular Therapy, 2025. Verfasst von Alhomidi Almotiri und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Shaqra University, Shaqra 15526, Saudi Arabia; European Cancer Stem …. Hauptthemen laut MEDLINE: Gene Editing, CRISPR-Cas Systems, Genetic Therapy, Hematologic Diseases. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 169 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Shaqra University, Cardiff University, Saudi Arabian Cultural Bureau.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In the setting of monogenic disease, advances made in genome editing technologies can, in principle, be deployed as a therapeutic strategy to precisely correct a specific gene mutation in an affected cell type and restore functionality. Using the β-hemoglobinopathies and hemophilia as exemplars, we review recent experimental breakthroughs using CRISPR-derived genome editing technology that have translated to significant improvements in the management of inherited hematologic disorders. Yet there are also challenges facing the use of CRISPR-mediated genome editing in these patients; we discuss possible ways to obviate those issues for furtherance of clinical benefit.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gene EditingCRISPR-Cas SystemsGenetic TherapyHematologic DiseasesHumansAnimalsHemophilia AMutationHemoglobinopathies

Stichwörter der Autor:innen

CRISPR-Cas technologygene editinghemophiliasickle cell diseasethalassemia

Autor:innen und Institutionen

  • Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Shaqra University, Shaqra 15526, Saudi Arabia; European Cancer Stem Cell Research Institute, Cardiff University, School of Biosciences, Ca…
  • Department of Biological Sciences, Faculty of Science, National University of Singapore (NUS), Singapore 119077, Singapore.
  • Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, The Hashemite University, Zarqa 13133, Jordan; European Cancer Stem Cell Research Institute, Cardiff University, School of Biosciences, Car…
  • Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, The Hashemite University, Zarqa 13133, Jordan.
  • European Cancer Stem Cell Research Institute, Cardiff University, School of Biosciences, Cardiff CF24 4HQ, UK. Electronic address: rodriguesn@cardiff.ac.uk.

Förderung

  • Shaqra University
  • Cardiff University
  • Saudi Arabian Cultural Bureau

Zitieren

APA

Almotiri, A., Abogosh, A., Abdelfattah, A., Alowaisy, D., & Rodrigues, N. P. (2025). Treating genetic blood disorders in the era of CRISPR-mediated genome editing. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2025.01.031

Vancouver

Almotiri A, Abogosh A, Abdelfattah A, Alowaisy D, Rodrigues NP. Treating genetic blood disorders in the era of CRISPR-mediated genome editing. Molecular Therapy. 2025. doi:10.1016/j.ymthe.2025.01.031

BibTeX
@article{Almotiri2025,
  author = {Almotiri, Alhomidi and Abogosh, Ahmed and Abdelfattah, Ali and Alowaisy, Dalya and Rodrigues, Neil P},
  title = {Treating genetic blood disorders in the era of CRISPR-mediated genome editing},
  journal = {Molecular Therapy},
  year = {2025},
  doi = {10.1016/j.ymthe.2025.01.031}
}
Kostenlos starten →